Loading…
Chinese vaccine maker using viral-vector technology, known for its COVID-19 vaccine and meningitis/rabies/Ebola vaccines.
Chinese vaccine maker using viral-vector technology, known for its COVID-19 vaccine and meningitis/rabies/Ebola vaccines.
Most of its non-COVID vaccines are sold on China's voluntary market, where people pay themselves via local disease-control centres rather than through state-funded programmes, so uptake depends on marketing and perceived need. COVID vaccine sales were once large but faded after the pandemic peak. This is the Hong Kong line of a dual-listed company.
In one line: China's viral-vector vaccine player.
Moat: narrow (IP / patents, regulatory licence). Proprietary viral-vector platform and China vaccine licences, but demand fell sharply post-pandemic.
Headquarters: Tianjin, China · Founded: 2009 · Employees: 1,134
Size CanSino Biologics (6185.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $1.71B, the 456th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$26.68 on 6 Nov 2026.
Performance Over six months the shares fell 5.5%, against -4.4% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 9th lowest of 18 in its peer set.
Growth Revenue grew 36.1% over the last twelve months (peer median +18.0%); the operating margin is -4.0% (peer median -171.6%).
Valuation It trades at 74.9× forward earnings against a peer median of 40.5× (2nd most expensive of 5).
Capital Return on invested capital runs 7.0 points below its cost of capital (8.8% WACC).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.43B | HK$1.15B | HK$894M | HK$381M | HK$1.20B |
| Revenue growth | — | +28% | +134% | -68% | — |
| Gross profit | HK$1.16B | HK$759M | HK$505M | -HK$1.09B | -HK$313M |
| EBITDA | n/a | HK$67.9M | -HK$217M | -HK$2.11B | -HK$1.50B |
| Net income | HK$34.6M | HK$30.2M | -HK$411M | -HK$1.64B | -HK$1.06B |
| Free cash flow | -HK$71.9M | -HK$170M | -HK$639M | -HK$1.72B | -HK$3.22B |
| Capital expenditure | HK$181M | HK$265M | HK$496M | HK$675M | HK$1.21B |
| Total debt | HK$1.09B | HK$1.44B | HK$2.14B | HK$2.97B | HK$3.03B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| CanSino Biologics 6185.HK | $1.71B | -5% | +36% | -4% | 74.9× | n/a |
| Chongqing Zhifei Biological Products 300122.SZ | $5.35B | -2% | -28% | -210% | n/a | -6.4% |
| Walvax Biotechnology 300142.SZ | $2.71B | -12% | -23% | 5% | 381.7× | 31.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6185.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -29.8% | -8.8% | 3rd lowest of 20 |
| 6-month return | -5.5% | -4.4% | 9th lowest of 18 |
| Distance from 52-week high | -44.2% | -38.6% | 8th lowest of 20 |
| Revenue growth (TTM) | +36.1% | +18.0% | 8th highest of 19 |
| Operating margin | -4.0% | -171.6% | 5th highest of 19 |
| Forward P/E | 74.9× | 40.5× | 2nd most expensive of 5 |
| ROIC minus cost of capital | -7.0 pp | -19.3 pp | 5th highest of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CanSino Biologics 6185.HK | Hong Kong | $1.71B | -5% | +36% | -4% | 74.9× | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.71B | -9% | +12% | 8% | n/a | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.72B | +45% | +16% | -5% | 166.7× | 45.1% | -2.5% |
| Stoke Therapeutics STOK | United States | $1.74B | -19% | -86% | -913% | n/a | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.68B | -40% | n/a | n/a | n/a | n/a | n/a |
| Absci ABSI | United States | $1.75B | +72% | -62% | -8,411% | n/a | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.68B | -4% | +56% | -737% | n/a | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.67B | -7% | +739% | 41% | n/a | -19.0% | +36.4% |
| Peptron 087010.KS | South Korea | $1.67B | -63% | +16% | -427% | n/a | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.76B | n/a | -55% | -593% | n/a | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.76B | -23% | +71% | 0% | 29.7× | n/a | n/a |
| Novavax NVAX | United States | $1.78B | +7% | -62% | -29% | n/a | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.64B | -44% | +90% | -297% | n/a | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 51.3× | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.83B | 0% | +556% | -43% | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 6.9× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | n/a | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | n/a | n/a | n/a |
| Zenas BioPharma ZBIO | United States | $1.84B | +44% | -93% | -27,390% | n/a | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | n/a | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |